Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.4 USD | -0.02% | +0.44% | +122.18% |
Jun. 02 | Transcript : Cullinan Therapeutics, Inc. - Special Call | |
Jun. 01 | Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+122.18% | 1.29B | |
+46.02% | 57.87B | |
+40.74% | 40.25B | |
-6.76% | 39.94B | |
-5.16% | 28.54B | |
+11.09% | 26.4B | |
-20.57% | 19.33B | |
+29.43% | 12.4B | |
-1.52% | 12.23B | |
+23.35% | 12.2B |
- Stock Market
- Equities
- CGEM Stock
- News Cullinan Therapeutics, Inc.
- Cullinan Oncology : HC Wainwright Adjusts Cullinan Management PT to $55 From $48, Maintains Buy Rating